SEARCH

SEARCH BY CITATION

References

  • 1
    Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001; 411: 36674.
  • 2
    Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 91721.
  • 3
    Satoh MS, Lindahl T. Role of poly (ADP-ribose) formation in DNA repair. Nature 1992; 356: 3568.
  • 4
    Lindahl T, Satoh MS, Poirier GG, Klungland A. Post-translational modification of poly (ADP-ribose) polymerase induced by DNA strand breaks. Trends Biochem Sci 1995; 20: 40511.
  • 5
    D′Amours D, Desnoyers S, D′Silva I, Poirier GG. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 1999; 342: 24968.
  • 6
    Bryant HE, Petermann E, Schultz N et al. PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J 2009; 28: 260115.
  • 7
    Yang YG, Cortes U, Patnaik S, Jasin M, Wang ZQ. Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks. Oncogene 2004; 23: 387282.
  • 8
    Schultz N, Lopez E, Saleh-Gohari N, Helleday T. Poly (ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res 2003; 31: 495964.
  • 9
    Arnaudeau C, Lundin C, Helleday T. DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells. J Mol Biol 2001; 307: 123545.
  • 10
    Murai J, Huang SY, Das BB et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 2012; 72: 558899.
  • 11
    Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 49: 507782.
  • 12
    Markovits J, Pommier Y, Kerrigan D, Covey JM, Tilchen EJ, Kohn KW. Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells. Cancer Res 1987; 47: 20505.
  • 13
    Sargent RG, Brenneman MA, Wilson JH. Repair of site-specific double-strand breaks in a mammalian chromosome by homologous and illegitimate recombination. Mol Cell Biol 1997; 17: 26777.
  • 14
    Magnusson J, Ramel C. Inhibitor of poly (ADP-ribose)transferase potentiates the recombinogenic but not the mutagenic action of alkylating agents in somatic cells in vivo in Drosophila melanogaster. Mutagenesis 1990; 5: 5114.
  • 15
    Waldman AS, Waldman BC. Stimulation of intrachromosomal homologous recombination in mammalian cells by an inhibitor of poly(ADP-ribosylation). Nucleic Acids Res 1991; 19: 59437.
  • 16
    Schreiber V, Hunting D, Trucco C et al. A dominant-negative mutant of human poly (ADP-ribose) polymerase affects cell recovery, apoptosis and sister chromatid exchange following DNA damage. Proc Natl Acad Sci USA 1995; 92: 47537.
  • 17
    Semionov A, Cournoyer D, Chow TY. Inhibition of poly (ADP-ribose)polymerase stimulates extrachromosomal homologous recombination in mouse Ltk-fibroblasts. Nucleic Acids Res 1999; 27: 452631.
  • 18
    Donawho CK, Luo Y, Luo Y et al. ABT-888, an orally active poly (ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007; 13: 272837.
  • 19
    Penning TD, Zhu GD, Gandhi VB et al. Discovery of the Poly (ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem 2009; 52: 51423.
  • 20
    Evers B, Drost R, Schut E et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008; 14: 391625.
  • 21
    Hay T, Matthews JR, Pietzka L et al. Poly (ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res 2009; 69: 38505.
  • 22
    Menear KA, Adcock C, Boulter R et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly (ADP-ribose) polymerase-1. J Med Chem 2008; 51: 658191.
  • 23
    Rottenberg S, Jaspers JE, Kersbergen A et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 2008; 105: 1707984.
  • 24
    Jones P, Altamura S, Boueres J et al. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly (ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem 2009; 52: 717085.
  • 25
    Löser DA, Shibata A, Shibata AK, Woodbine LJ, Jeggo PA, Chalmers AJ. Sensitization to radiation and alkylating agents by inhibitors of poly (ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Mol Cancer Ther 2010; 9: 177587.
  • 26
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74108.
  • 27
    Shimada H, Nabeya Y, Okazumi S et al. Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. Surgery 2003; 133: 48694.
  • 28
    Sekiguchi H, Akiyama S, Fujiwara M et al. Phase II trial of 5-fluorouracil and low-dose cisplatin in patients with squamous cell carcinoma of the esophagus. Surg Today 1999; 29: 97101.
  • 29
    Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986; 83: 89235.
  • 30
    Borghesi S, Hawkins MA, Tait D. Oesophagectomy after definitive chemoradiation in patients with locally advanced oesophageal cancer. Clin Oncol (R Coll Radiol) 2008; 20: 2216.
  • 31
    Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005; 434: 9137.
  • 32
    Saleh-Gohari N, Bryant HE, Schultz N, Parker KM, Cassel TN, Helleday T. Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks. Mol Cell Biol 2005; 25: 715869.
  • 33
    Lim DS, Hasty P. A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53. Mol Cell Biol 1996; 16: 713343.
  • 34
    Tsuzuki T, Fujii Y, Sakumi K et al. Targeted disruption of the Rad51 gene leads to lethality in embryonic mice. Proc Natl Acad Sci USA 1996; 93: 623640.
  • 35
    Sonoda E, Sasaki MS, Buerstedde JM et al. Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death. EMBO J 1998; 17: 598608.
  • 36
    Turner N, Tutt A, Ashworth A. Hallmarks of “BRCAness” in sporadic cancers. Nat Rev Cancer 2004; 4: 8149.
  • 37
    Vesprini D, Narod SA, Trachtenberg J et al. The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers. Can Urol Assoc J 2011; 5: E315.
  • 38
    Plummer R, Jones C, Middleton M et al. Phase I study of the poly (ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008; 14: 791723.
  • 39
    Rajan A, Carter CA, Kelly RJ et al. A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res 2012; 18: 234451.
  • 40
    Mukhopadhyay A, Elattar A, Cerbinskaite A et al. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly (ADP-ribose) polymerase inhibitors. Clin Cancer Res 2010; 16: 234451.
  • 41
    Davies SL, North PS, Hickson ID. Role for BLM in replication-fork restart and suppression of origin firing after replicative stress. Nat Struct Mol 2007; 14: 6779.
  • 42
    Petermann E, Orta ML, Issaeva N, Schultz N, Helleday T. Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair. Mol Cell 2010; 37: 492502.
  • 43
    Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010; 10: 293301.
  • 44
    Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008; 26: 378590.